Monday, May 12, 2008

Practice-Changing Clinical Data Anticipated By Medtronic

Medtronic Anticipates 'Practice-Changing' Clinical Data for Interventional Cardiologists at EuroPCR

ENDEAVOR II Four-Year Results, Updated ENDEAVOR Pooled Safety Analysis, One-Year Results from E-Five Registry and TAPAS Trial - All Feature on Meeting's Scientific Program

MINNEAPOLIS-- May 12, 2008 --Medtronic, Inc. (NYSE:MDT), today announced plans for the release of new clinical data on the Endeavor® Zotarolimus-Eluting Coronary Stent System and the Export® Aspiration Catheter at EuroPCR in Barcelona this week, May 13-16.

"New data from the ENDEAVOR clinical program and the TAPAS trial have the potential to be practice-changing for interventional cardiology," said Prof. Anthony Gershlick of University Hospitals of Leicester in the UK. "As the evidence from this clinical research continues to build, it shows more and more definitively the advantages of the Endeavor drug-eluting stent for a broad range of patients with coronary artery disease and of thrombus aspiration with the Export Aspiration Catheter for a specific group of patients suffering myocardial infarction."

A summary of the data presentations related to Medtronic's product portfolio for interventional cardiology at EuroPCR follows:

    * On Tuesday, May 13, the late-breaking clinical trials session from 15:30 - 18:30 in Room 1 includes presentations by:

- Dr. Jean Fajadet (at approximately 15:45) of the four-year results from ENDEAVOR II, a prospective, randomized, multicenter, controlled trial that compared the Endeavor drug-eluting stent to the Driver bare-metal stent.
                                                        
- Prof. Bart de Smet (at approximately 16:30) of one-year results from TAPAS, a single-center trial designed to evaluate the effect of thrombus aspiration preceding percutaneous coronary intervention by using the Export Aspiration Catheter in patients with acute myocardial infarction.

    * On Thursday, May 15, the Medtronic-sponsored symposium titled "Patients and Stents: Learning and Progress," 5:00 - 6:30 pm in Room 1, features presentations by:

- Prof. Martin Rothman on the one-year results of 8,300 patients in E-Five, an international registry that investigated the performance of the Endeavor drug-eluting stent in routine clinical practice.
                                                        
- Prof. Ian Meredith on the updated ENDEAVOR pooled safety analysis, which includes 2,132 Endeavor patients (from ENDEAVOR I, II, II continued access, III and IV) - 678 of whom have now been followed for four years, 1,271 for three years, 1,290 for two and 2,093 patients for one year.

All times are local to Barcelona. Room numbers are for The Forum CCIB Convention Center, the venue for EuroPCR.

"The data we're presenting this week at EuroPCR illustrate the depth of innovation within the CardioVascular business at Medtronic and the growing breadth of our offering to interventional cardiologists," said Scott Ward, senior vice president of Medtronic and president of the CardioVascular business. "We are particularly excited to share the long-term results from the ENDEAVOR clinical program, which continue to illustrate significant performance advantages for patients and physicians, positioning Medtronic for market leadership in coronary stents."

In addition to attending these data presentations and other educational and scientific sessions, EuroPCR participants are encouraged to visit the Medtronic exhibit (booth #D04), which will feature highlights of the company's current and future cardiovascular innovations, including the:

    * Endeavor and Endeavor Resolute Zotarolimus-Eluting Coronary Stent Systems
    * Sprinter Legend Balloon Catheter
    * Export XT Aspiration Catheter
    * Defender Embolic Protection Filter
    * Complete SE (Self-Expanding) Peripheral Stent
    * Assurant Cobalt Balloon-Expandable Iliac Stent
    * Melody Transcatheter Pulmonic Heart Valve

Information on Medtronic's programs designed to foster "Innovation through Collaboration" in the fields of educational development (Academia) and clinical science (Scientia) will also be available at EuroPCR.

"As the trend of closer collaboration across medical specialties continues, our CardioVascular business is uniquely positioned to forge the partnerships necessary to find novel solutions to unmet patient needs," Ward added. "As the theme of our EuroPCR exhibit, 'Better Together,' suggests, we know from decades of experience the profound power of collaboration with the clinical community in the service of patients with chronic diseases."

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.

Contacts

Medtronic, Inc.
Joe McGrath, 707-591-7367 (Public Relations)
Jeff Warren, 763-505-2696 (Investor Relations)

0 Comments:

Post a Comment

<< Home